Gilead Sciences Inc.
Gilead Sciences Settles Patent Litigation with Generic Manufacturers
Summary
On October 6, 2025, Gilead Sciences, Inc. announced settlement agreements with Lupin Ltd., Cipla Ltd., and Laurus Labs Ltd. to resolve patent litigation over generic versions of Biktarvy. The settlements delay generic entry until April 1, 2036, in the United States. Gilead also furnished an interactive data file as part of this filing.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement